Author:
Fendler Annika,Shepherd Scott T C,Au Lewis,Wu Mary,Harvey Ruth,Schmitt Andreas M,Tippu Zayd,Shum Benjamin,Farag Sheima,Rogiers Aljosja,Carlyle Eleanor,Edmonds Kim,Del Rosario Lyra,Lingard Karla,Mangwende Mary,Holt Lucy,Ahmod Hamid,Korteweg Justine,Foley Tara,Barber Taja,Emslie-Henry Andrea,Caulfield-Lynch Niamh,Byrne Fiona,Deng Daqi,Kjaer Svend,Song Ok-Ryul,Queval Christophe,Kavanagh Caitlin,Wall Emma C,Carr Edward J,Caidan Simon,Gavrielides Mike,MacRae James I,Kelly Gavin,Peat Kema,Kelly Denise,Murra Aida,Kelly Kayleigh,O'Flaherty Molly,Shea Robyn L,Gardner Gail,Murray Darren,Yousaf Nadia,Jhanji Shaman,Tatham Kate,Cunningham David,Van As Nicholas,Young Kate,Furness Andrew J S,Pickering Lisa,Beale Rupert,Swanton Charles,Gandhi Sonia,Gamblin Steve,Bauer David L V,Kassiotis George,Howell Michael,Nicholson Emma,Walker Susanna,Larkin James,Turajlic Samra
Funder
The Royal Marsden Cancer Charity
Reference13 articles.
1. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study;Fendler;Nature Cancer,2021
2. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer;Fendler;Cancer Cell,2022
3. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization;Cele;Nature,2021
4. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant;Gruell;Research Square,2021
5. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection;Nemet;N Engl J Med,2021